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Foods in diet contain numerous chemical small
compounds, which have some bioactivities in human.
Enormous tests of food chemicals in vitro are not
always linked to detect physiological activity in human
body and also can not rationally explain the efficacy of
traditional Chinese medical herbs except some com-
pounds with strong activity. The efficacy of chemical
compounds extracted from traditional Chinese medical
herbs may be explained by either assembly in combina-
tion of compounds or little reaction of single compounds
in the present biological evaluation. The interaction
between proteins and small compounds has been
studied in medicinal chemistry but poorly in food chem-
istry because of their different business values in
success. Nevertheless, the use of herbs and supple-
ments is prevalently popular in Japan. Yakuzen-
Dietetics, which defines as diets contributed for
prevention of diseases, delivery of nutritional elements
and assisting medical treatments, needs to clarify the
physiological efficacy of public herbs in physiological
conditions by novel approaches such as omics-
technologies and studies for protein-small moleule inter-
action. Protein-small molecule interaction is an
important and confronted problem because all physio-
logical actions are based on protein-ligand interaction.
Protein-ligand interaction has been advanced to de-
termine 3D structures by X-ray crystallography,
nuclear magnetic resonance spectroscopy, fluorescence,
Raman spectroscopy and their combination. Although
static structures are known for many proteins, the
dynamic change of proteins in reactions is unknown.
Proteins are dynamic molecules and often undergo con-
formational change upon ligand binding. Flexible loop
regions in proteins are believed to have a critical func-
tional role in protein-ligand binding. Rigid regions in
proteins also are related to hot spots in protein-protein
interaction. Therefore, there may be some patterns for
protein dynamism in protein-protein interaction. In this
review, I discuss studies related to conformation and
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Abstract
The potential for driving force in protein-ligand binding are discussed in this review. The conformational
change in protein-ligand interaction is dependent on characteristics of proteins. Proteins which do not change con-
formation before ligand binding compose of constraint binding site residues. The conformation of ligand-binding
sites of these proteins adopts disallowed Ramachandran angels. Conformational changes in protein-ligand binding
result to adopt energetically unfavorable or disallowed Ramachandran angels. These findings show that an
element of driving forces in protein-ligand binding may be the generation of torsion-angle strain.
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Introduction
torsion strains in protein-ligand interaction and present
the interaction between small compounds and TNF-
TNFR system as a challenging example in protein-
ligand binding.
Conformation and torsion strains in
protein-ligand interaction
The process of ligand-receptor binding often
contains conformational changes in structures.
Conformational change includes both backbone and side
chain movements１ . The conformation in backbone
structures changes domain motion such as hinge motion
and loop structure around rigid structures. Side chain
conformational changes are often in flexible loop struc-
ture on rigid structures. Conformational changes may
perform in the range of own protein flexibility, which
accompanies free energy changes. To consider driving
force of conformational changes, proteins with metal
binding sites is exampled. Metal binding in proteins con-
tributes structural stability and acts as cofactors to
function catalysis and protein binding. In the compari-
sons of 3D structures between unbound state and metal
bound state in the Protein Data Bank (PDB), more than
40% of the binding sites revealed rearrangements of
conformation including the backbones２. Metal ion inter-
acts with ionic residues such as aspartate, glutamate,
cystein and histidine to make conformation change.
Since metal ion has concrete structure, the driving force
of the conformational change is electrostatic energy of
metal-ionic residue interaction. The electrostatic inter-
action provides energy to exceed transition state for the
conformational change. In other driving force of confor-
mational changes, hydrogen bonds, hydrophobic inter-
actions and van der Waals packing relate to
conformational change as a result of comparison of
structures between bound state and unbound state.
Conformational changes often accompany to change
protein strain energies because ligands binding to
proteins induce deformation. The intra-molecular elec-
trostatic interaction in histidine-containig
phosphocarrier protein (HPr) induces a conformational
change to form the active center in the sequence of His-
Ala-Arg３. The conformation of HPr active center adopts
energetically unfavorable or disallowed Ramachandran
angels. Conformational changes in protein-ligand inter-
action are dependent on characteristics of proteins.
Proteins which do not change conformation before
ligand binding compose of constraint binding site
residues. Interestingly, the conformation of ligand-
binding sites of these proteins also adopts disallowed
Ramachandran angels４ . The state having disallowed
Ramachandran angels in ligand binding sites locally
generates torsion-angle strain clusters. These findings
show that one of the binding potential in proteins may
prerequisite the generation of torsion-angle strain
clusters rather than conformational changes. The
release of torsion-angle strain may produce enough
energy to form transition state of complex. In protein
dynamics, energy landscape generally represented as
the hierarchy of protein dynamics and energy barrire
r５,６. For ligand-protein binding, the energy landscape
is the free energy determined such as bond vibration,
side chain rotation, loop motion, domain motion and
solvation. Entropy changes may compensate by
changing conformations of ligands and/or receptors. In
fact, comparisons of 3D structures between bound and
unbound structures in PDB show ligand-induced
protein conformational changes in backbone structures
as well as binding sites７. Nevertheless, the relationship
between protein conformations and driving forces in
ligand-protein binding is unclear. The torsion-angle
strain is one of the candidates for critical driving force
in protein-ligand binding. In designing torsion-angle
strain clusters, the presence of glycine residues in func-
tional loops may be important because glycine residues
are the highest occurrence in loops to comply with the
geometrical constraints. Since the glycine residue
provides large allowed conformational space or is not re-
stricted to the regions of Ramachandran plot appropri-
ate to the other amino acids with side chains, the
presence of glycine residue may be rational for
adequate energy landscape. In fact, the relative fre-
quency of glycine in loops is shown to correlate to the
number of state having disallowed Ramachandran
angels by analyzing a bank of loops from three to eight
residues long from PDB８. These findings indicate that
target regions in proteins for discovery of ligands may
be in turns with glycine residues with disallowed
Ramachandran angels.
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Functional conformation and interfaces in
protein-ligand binding
In the search of protein interfaces, the selection of
loop motifs is important for designing peptides because
binding site residues adopting disallowed conformations
are classified as gamma-turn and beta-turn conforma-
tions. Loop structures are often present in the interface
of protein-ligand binding and can change their confor-
mations. Although loops were originally described as
random coil, the increased loops in 3D structures could
be structurally classified by loop geometry, three angles
and one distance between connected secondary struc-
tures and Ramachandran pattern. The loop between
connected secondary structures occupies 80% of short
loops with less than 10 amino acids. The loops are func-
tionally separated into two groups. The one is just to
contribute globular formation of proteins to stabilize
and prefers to the shortest loops broken alpha-helices or
beta-sheets. The other is functional loops which
generate interfaces for protein-ligand binding and
binding pockets. Functional loops often make conforma-
tion change in protein-ligand binding. The areas of
contact surface is broad from 100 Å to 3000Å in
protein-ligand binding and is dependent on the
molecular size of ligands. The small ligands such as
enzymes, G-protein-coupled receptors and allosteric
pockets have been designed to be generated in medici-
nal chemistry. The large contact surfaces in protein-
ligand binding have never been designed because of
little example to know how to begin study on this case.
Consequently, there is an interesting problem for un-
derstanding energy landscape in protein-protein inter-
action as well as an enormous therapeutic potential in
challenging to design large contact surface in protein in-
teraction. One of the approaches is used for antibodies
which have been developed for humanization from
mouse monoclonal antibodies, preparing from human
peripheral lymphocytes, protein engineering for phar-
maceutics and cell culture for antibody production, but
the concept of antibody still remains in large contact
surface interaction to oblige higher cost and time
consume. Challenging approaches are now underway to
understand the element of large contact surface interac-
tion and to create small molecules bound or disrupted
protein-protein binding to large contact surface. The
practice is either high throughput screening (HTS) for
chemical libraries or mimetics of interfaces of protein by
fragmentation. These approaches seem to be technically
independent each other, but have a common basic
element. HTS must make libraries invest a lot of con-
cept-based compounds with potentials to raise confor-
mational change or binding energy. Equally, fragment
mimics must not extract the only sequences of inter-
faces in complex but the potentials of conformational
change or binding energy. In the behind, both ap-
proaches are introduced with tumor necrosis factor
(TNF) and its receptor.
Energy landscape and binding active sites
in proteins
The pathway of protein-ligand binding is two
mechanisms９,10 , which are named as conventional in-
duced-fit and population-shift11 (conformational selec-
tion). Both mechanisms perform in the dependence on
protein concentration10 as well as types of proteins. The
common element is conformational change before or
after ligand binding. The motion of functional conforma-
tions accompanies to increase free energy of a protein in
the unbound protein. Steric strain energy, which arises
from rotation around disallowed torsion angles, is con-
tributed to the increase of free energy in protein
binding and is released to form a complex12. This finding
agrees with the active sites of proteins with or without
changing conformation often exist the state having dis-
allowed Ramachandran angels. Therefore, steric strains
may be necessary in designing ligands.
Interaction between TNF and TNF receptor
families
Tumor necrosis factor (TNF) was identified as
products of lymphocytes and macrophages and caused
the lysis of certain types of cells, especially tumor cells.
At the same time, TNF was cloned to be found identical
to cachectin, mediator of cachexia. Then, several studies
have demonstrated important roles in the field of in-
flammatory such as rheumatoid arthritis, Crohn's
disease and septic shock. Moreover, TNF was a
member of adipocytokines related to diabetes13 ,
atherosclerosis14 and bone metabolism15 . The DNA
cloning of TNF receptors led to discovery of TNF re-
ceptor-related superfamily proteins (TNFR SFPs)16 ,
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which related to host defense, inflammation, apoptosis,
autoimmunity, and organogenesis. Since TNF is an im-
portant role in trigger of inflammatory pathway, the in-
hibition of TNF has been investigated as
pharmacological target. The production or action of
TNF was inhibited by TNF soluble receptor17－20 ,
glucocorticoids, phosphodiesterase inhibitors, anti-
inflammatory cytokines (IL-10 and IL-4), cholinergic
anti-inflammatory pathway, inhibitors of NF κ B,
metalloprotease inhibitors, thalidomide and p38
mitogen-activated protein kinase inhibitors.
TNF is expressed as a membrane-embedded form,
in which TNF is cleavaged to form soluble mature and
is released as active trimers. The 17,350-dalton mono-
mer forms an elongated, antiparallel beta-pleated sheet
sandwich with a ‶jelly-roll" topology. Three monomers
associate intimately about a 3-fold axis of symmetry to
form a compact bell-shaped trimer (Fig. 1)21.
The TNF ligand family, TNF-beta (LT alpha) and
TNF-alpha (LT beta) interact in a complex fashion of
cross-binding to their receptors (TNFR p55, TNFR p75,
and TNFR-RP). Two soluble TNF-binding proteins are
derived from the extracellular domains of the p55 and
p75 TNF receptors. The extracellular domains of the
two receptors each contain four similar cysteine-rich
repeats of about 40 amino acids, in common with several
other cell surface proteins including the p75 nerve-
growth-factor receptor and the CD40 and Fas antigens.
The complex with TNF ligand and TNFR is considered
to form TNF trimers covered with TNFR trimers. The
structure of the complex22 is shown as a monomeric
view in Figure 2.
In the complex of TNF beta-TNFR p55, the flexible
loop structure of TNF beta interacts with the longer
face consisted of the sequence of HCLSCSKSRKEMGQ
and the short loop with the sequence of FTASEN in
TNFR. The static interface of the two sequences in
TNFR provide the design of cyclic peptides, but TNF
inhibition of their peptides were little activities23. On the
other hand, beta-turn structure with the sequence of
WSENL in TNFR, which is located near the interface of
complex, was successful to peptidomimetics with
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Fig. 1 The structure of mouse tumour-necrosis factor alpha (mTNF). The structures of mTNF and human
TNF are very similar.
Fig. 2 The structure of the complex of the extracellular
domain of the human 55 kd tumor necrosis factor
(TNF) receptor with human TNF beta.
moderate TNF inhibitory activity (IC50 =5 μM in
receptor binding assay)23. These findings indicate that
the important dynamic region of TNFR to interact with
TNF may be also present near the static interface
regions. The region of WSENL sequence in TNFR may
induce conformational changes in forming the complex
of TNF-TNFR24 . Therefore, the discovery of a key
region for diriving force of conformational change may
be important for designing ligands. On the other hand,
HTS provided to discover non-peptidic small compound
to inhibit TNF-alpha TNFR binding with KD=13 μM25.
The mechanism of this compound is to disrupt the
trimer of TNF-alpha. This research indicates that there
is a wedge-driven region to disrupt the trimer mainte-
nance. Both compounds revealed the same order of in-
hibitory activity. Although two approaches are different
technology, the potentials of the compounds was equiva-
lent in the inhibition of TNF bound TNFR. The drug
candidates for targets with small contact surface will
make their biological activities improve by normal lead
optimization, but the candidates with large contact
surface provide no guarantee for lead optimization in
conventional approach because of no precedents. Even
lead optimization as well as discovery of leads for
targets with large contact interface is a challenging
task. In this way, the most advanced research just
launches to elucidate protein-small-molecule binding.
We will be encouraged to understand protein-small
molecule binding by integrated information such as 3D
structure and energy landscape in protein-protein inter-
action, identification of driving force for conformational
changes and discovery of potential compounds.
Perspective in the future
Targets with large contact surface in protein-ligand
binding such as growth factors and cytokines has been
buried in fantasy. 3D structures in PDB provide the
comparisons of protein-ligand complexes and their
ligand-free proteins to understand the critical relation
between loops and glycine residues with disallowed
Ramachandran angels. Moreover, inhibitory compounds
against targets with large contact surface have discov-
ered. The protein-ligand interactions related to large
contact surface will be an important therapeutics with
advance on understanding energy landscape, especially
steric strain energy in conformation, in protein-protein
interaction.
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